Inveltys is a prescription eye drop used to treat inflammation and pain after eye surgery. It contains loteprednol etabonate at a 1% concentration, making it a corticosteroid designed specifically for post-operative recovery. The FDA approved it for this single indication, and its main advantage over older formulations is that it only needs to be used twice a day instead of four times.
How Inveltys Works
Like other corticosteroid eye drops, Inveltys reduces the swelling and pain that naturally follow eye surgery, most commonly cataract procedures. What sets it apart is a drug delivery technology called mucus-penetrating particles (MPP). Your eye’s surface is coated in a layer of mucus that traps and washes away most of what lands on it, including medication. Standard eye drops lose a significant portion of their active ingredient to this barrier.
Inveltys gets around this problem by packaging the drug into nanoparticles with a specialized coating that slips through the mucus layer rather than getting stuck in it. These particles are small enough to avoid the dense mesh of mucus fibers and have surface properties (strongly water-attracting and electrically neutral) that prevent them from sticking. The result is that the drug stays on the eye’s surface longer and more of it actually reaches the tissues where inflammation is happening. This enhanced penetration is what allows a twice-daily dose to do the work that older formulations needed four daily doses to accomplish.
How It Compares to Older Loteprednol Drops
The most direct comparison is with Lotemax, an older loteprednol product at 0.5% concentration that requires four drops per day. Inveltys delivers the same active ingredient at double the concentration but half the dosing frequency. For patients recovering from surgery and juggling multiple eye medications, going from four times daily to twice daily is a meaningful convenience. The nanoparticle technology compensates for the reduced number of doses by getting more drug into the eye with each drop.
Clinical Trial Results
Inveltys was tested in two large, placebo-controlled trials involving 771 patients who had developed significant inflammation after cataract surgery. These patients were randomly assigned to receive either Inveltys or a placebo (the liquid vehicle without any active drug), and researchers measured two outcomes: complete resolution of inflammation, defined as zero inflammatory cells visible under a slit-lamp microscope, and complete resolution of pain, defined as patients reporting no pain at all.
By day 15 after surgery, nearly 70% of patients using Inveltys reported complete pain resolution. Inflammation clearance was also significantly better than placebo across both studies, with assessments taken at days 4, 8, and 15 post-surgery.
Dosing and How to Use It
The standard regimen is one to two drops in the affected eye twice daily. You start the day after surgery and continue for two weeks. Before each use, shake the bottle for one to two seconds, since the medication is a suspension that settles when sitting still.
A few practical details matter for getting the most from each dose. Wash your hands before applying the drops. Don’t let the dropper tip touch your eye, your fingers, or any surface, as this can introduce bacteria. If you’re using other eye medications at the same time, wait at least five minutes between each one so the drops don’t wash each other out. Contact lens wearers should remove lenses before applying and wait 15 minutes before putting them back in. Store the bottle upright at room temperature (59°F to 77°F) and don’t freeze it. Replace the pink cap after every use.
Common Side Effects
The most frequently reported side effects in clinical trials were mild and expected for a post-surgical eye drop: inflammation in the front chamber of the eye, eye pain, and a sensation of something in the eye. Other effects that occurred in 1% to 10% of patients included corneal surface changes, eye discharge, discomfort, dry eye, excessive tearing, redness, itching, and burning when the drop is first applied.
Less common effects, occurring in under 1% of patients, included blurred vision, light sensitivity, and eye irritation. Because Inveltys is a steroid, prolonged use carries the risk of elevated eye pressure, which can damage the optic nerve over time, as well as cataract formation behind the lens. These risks are a concern with any corticosteroid eye drop, which is one reason the treatment course is kept short at two weeks.
Who Should Not Use Inveltys
Inveltys is not appropriate for eyes with active viral, fungal, or mycobacterial infections. Steroid eye drops suppress the local immune response, which is exactly what you want after surgery but dangerous when an infection is present. Using a corticosteroid during an active eye infection can allow the infection to spread unchecked and worsen significantly. Your eye surgeon will evaluate for any signs of infection before prescribing it.